PHIO PHARMACEUTICALS CORP. Accounts Payable and Accrued Liabilities
PHIO PHARMACEUTICALS CORP. (PHIO) had Accounts Payable and Accrued Liabilities of $1.71 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Accounts Payable and Accrued Liabilities
us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable and Accrued Liabilities $1.71M.
- 2026-03-31: Accounts Payable and Accrued Liabilities $950.00K.
- 2025-12-31: Accounts Payable and Accrued Liabilities $1.34M.
- 2025-09-30: Accounts Payable and Accrued Liabilities $1.67M.
| Period end | Accounts Payable and Accrued Liabilities |
|---|---|
| 2026-06-30 | $1.71M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $950.00K 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.34M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $1.67M 10-Q · filed 2025-11-13 |
| 2024-12-31 | $1.01M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |